Major Depression Disorder: Symptomatology and Current Treatment
===============================================================

Major depression disorder (MDD) is one of the most debilitating disorders in the world, and the most commonly diagnosed according to the World Health Organization. The Diagnostic and Statistical Manual in its last edition (DMS-5) defines this disorder as a set of symptoms including: depressed mood, decreased interest or pleasure in almost all activities nearly every day, appetite changes (changes in body weight), sleep disturbances, feelings of worthlessness or guilt, diminished ability to concentrate or indecisiveness, psychomotor agitation or retardation and fatigue or loss of energy ([@B2]).

Although depression is typically defined as an affective disorder, it also appears that some symptoms such as psychomotor retardation, fatigue, and loss of energy are related to deficits in motivation, specifically in activational aspects of motivation. Motivated behavior is directed toward or away from particular stimuli, but it also is characterized by a high degree of activity, effort, vigor, and persistence ([@B148], [@B150]). People with depression commonly show profound activational impairments, such as lassitude, listlessness, fatigue, and anergia (low self-reported energy) that affect their motivation ([@B180]; [@B168]). In fact, among depressed people, energy loss and fatigue are the second most commonly reported symptoms, only behind depressed mood itself ([@B180]), and depressed patients with anergia are more common than patients with anxiety related symptoms ([@B180]; [@B34]). Furthermore, in depressed patients "lack of energy" was the factor that correlated to problems with fatigability, inability to work, and psychomotor retardation, loading most strongly onto a second order general depression factor ([@B60]). Many people with MDD have fundamental deficits in reward seeking, exertion of effort, and effort-related decision making that do not simply depend upon any problems that they may have with experiencing pleasure ([@B179]). Lack of energy is the symptom most highly correlated with a lack of social function in depressed patients, and is correlated with various work-related impairments such as days in bed, days of lost work, and low work productivity ([@B172]). In addition, this cluster of symptoms can be highly resistant to treatment ([@B168]); they are the best predictors of lack of remission after antidepressant drug treatment ([@B168]; [@B55]).

Pharmacological Treatments for the Activational Symptoms in Depression
======================================================================

The severity of effort-related motivational symptoms in depression is related to problems with social function, employment absence, and treatment outcomes ([@B180]; [@B168]). Patients with high scores in psychomotor retardation also have longer duration of illness, an earlier age of onset, and more depressive episodes ([@B12]; [@B55]). These symptoms are a predictor of delayed response to treatment with either interpersonal psychotherapy or selective serotonin (5-HT) reuptake inhibitor pharmacotherapy ([@B46]), often remaining as residual symptoms even in patients in remission ([@B168]; [@B39]; [@B55]).

Most of the present treatment strategies for MDD focus on drugs that block the inactivation (i.e., inhibitors of enzymatic breakdown or uptake) of the monoamine neurotransmitters 5-HT and norepinephrine (NE). The classical antidepressants include monoamine oxidase inhibitors (MAOIs), which affect one of the major catabolic enzymes for monoamines ([@B131]), and drugs that inhibit uptake of one or more monoamines ([@B40]; [@B191]). Although 5-HT and NE reuptake inhibitors have become the most frequently prescribed medications for MDD, they fail to complete symptom remission in 40--60% of all patients ([@B144]; [@B39]), and it is widely accepted that at least 20% of all depressed patients do not respond adequately to most antidepressant drugs ([@B22]). Many common antidepressants, including 5-HT transport inhibitors such as fluoxetine, are relatively ineffective at treating anergia and fatigue, and in fact, can induce or exacerbate these symptoms ([@B114]; [@B169]; [@B39]).

Interestingly, some clinical studies suggest that drugs that inhibit dopamine (DA) transport, such as the catecholamine uptake inhibitor bupropion, are relatively more effective than 5-HT uptake inhibitors for treating effort-related motivational symptoms ([@B132]; [@B168]; [@B30]; [@B115]). Furthermore, individual differences in behavioral traits can differentiate between depressed patients that are more responsive to bupropion (i.e., motivated, achievement-oriented, active, exercise-oriented people) vs. fluoxetine (people with mood problems, irritability, and rumination) ([@B8]). Stimulant drugs that are not considered to be antidepressants in the classical sense, such as methylphenidate and modafinil, have been shown to increase energy and motivation in depressed patients ([@B198]). Thus, clinical studies, together with preclinical investigations (e.g., [@B146], [@B151]; [@B150]; [@B3]; [@B64]), have led to the suggestion that DA systems and related circuits are particularly involved in effort-related motivational symptoms.

Adenosine Receptors Co-Localization with DA Receptors
=====================================================

In addition, another possible therapeutic target for the anergia component of depression is adenosine receptors. Adenosine is a neuromodulator in the central nervous system (CNS) that plays an important role in the regulation of synaptic transmission and neuronal excitability ([@B23]; [@B158]). Several subtypes of adenosine receptors are expressed in the brain, with A~1~ and A~2A~ G-protein-coupled receptors being the most abundant ([@B69]; [@B49]). A~2A~ receptors are expressed at high levels in the striatum and olfactory bulbs and tubercle ([@B49]), but also in areas such as amygdala, hippocampus or prefrontal cortex ([@B26]; [@B117]; [@B162]). Adenosine A~1~ receptors have a higher widespread distribution in the brain, with a somewhat higher concentration in hippocampus ([@B157]). All these regions are involved in the regulation of complex processes such as cognition, motivation, and emotion ([@B63]; [@B150]) that seem to be altered in MDD.

The spatial distribution of adenosine receptors within the brain ([@B49]) allows a wide range of effects, including modulation of other neurotransmitter systems ([@B23]). Thus, adenosine A~2A~ receptors are highly expressed postsynaptically in DA rich areas such as neostriatum and accumbens (Acb) ([@B71]; [@B72]; [@B29]; [@B137]). In fact, it has been demonstrated that in these areas, there is a functional interaction between DA D~2~ and adenosine A~2A~ receptors (see **Figure [1](#F1){ref-type="fig"}**), which are co-localized on enkephalin-containing medium spiny neurons and converge onto the same signal transduction pathways in an antagonistic way ([@B43], [@B44]; [@B52]; [@B42]; [@B7]). Similarly, A~1~ and D~1~ receptors antagonistically interact on substance P-containing medium spiny neurons ([@B43], [@B44]).
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The behavioral significance of this interaction has frequently been studied in the context of neostriatal motor functions and pathologies ([@B43]; [@B19]; [@B16]). Thus, selective A~2A~ receptor antagonists are being tested in clinical trials for pathologies involving DAergic dysfunctions such as Parkinson disease, and positive results indicate that they can be used as adjuvant therapies ([@B67]). Caffeine actions on A~1~ and A~2A~ adenosine receptors ([@B42]), has promoted its study as an alternative preventive or therapeutic tool for parkinsonian symptoms ([@B130]). Moreover, within the last years, the motivational significance of DA-adenosine receptor interactions has become apparent with regard to processes such as behavioral activation, and effort-related decision-making impaired in depression or other pathologies ([@B146]; [@B149]).

In the present review, we focus on studies that assessed the effect of adenosine antagonists on different aspects of depression in humans, as well as in animal models. Special emphasis will be placed on motivational/psychomotor symptoms induced by DA depletions and studies related to DA-adenosine interactions in pathological symptoms related to effort-related decision-making.

Caffeine Consumption and Depression
===================================

Caffeine is a naturally occurring methylxanthine that acts mainly as a non-selective A~1~ and A~2A~ adenosine receptor antagonist ([@B48]). This methylxanthine is found in common beverages including coffee, tea, soft drinks, and products containing cocoa, as well as a variety of medications and dietary sources ([@B6]; [@B185]), ranking as one of the most commonly consumed dietary ingredients throughout the world ([@B65]). Daily intake of caffeine among consumers in United States is about 280 mg, and higher intakes are estimated in some European countries ([@B6]). Caffeine is typically consumed in order to increase alertness, arousal and energy ([@B99]). Its consumption has been related to changes in cognitive performance and mood in normal population ([@B166]; [@B121]). However, it enhances performance more in fatigued than well-rested subjects ([@B95]; [@B13]).

There are very few studies on the relation between caffeine consumption and depression-related symptoms, and in many cases, its use is related to self-medication patterns. Some of these studies focus on the role of caffeine as a drug that prevents depression, while others discuss caffeine as a possible treatment for existing depression. Thus, secondary analyses of large epidemiological databases with similar number of men and women indicate that in non-clinical samples that do not work, consumption of caffeine (around 150 mg/day as average) was associated with a reduced risk of depression ([@B165]). Also, in a longitudinal study in women free from depressive symptoms at baseline, high levels of caffeine consumption (\>550 mg/day) was negatively correlated with the appearance of depressive symptoms ([@B96]). In fact, the relative risk for depression was highest for those women with lower caffeine consumption (\<100 mg/day) ([@B96]). However, in women with multiple sclerosis high doses of caffeine (\>400 mg/day) increased the prevalence of MDD ([@B122]). Moreover, in non-clinical samples, although caffeine consumption at moderate doses was related with decreases in suicide risk ([@B83]; [@B176]; [@B97]), excessive consumption (750 mg/day) was correlated with a higher risk of suicide ([@B83]; [@B175]; [@B97]). Thus, from the present studies, it seems that intermediate levels of caffeine consumption (300--550 mg/day) produce beneficial effects in non-clinical populations, but not in people with some neurological pathologies. Higher doses will have negative effects, even in non-clinical populations.

Multiple reports have lent support to the idea that depressed people could use caffeine as self-medication. It has been reported that psychiatric patients show a relatively high degree of caffeine consumption compared to the normal population ([@B56]; [@B88]; [@B140]). This appears to be particularly true in patients that have experienced depressive symptoms ([@B88]). Different profiles of patients (i.e., with alcohol dependence, seasonal affective disorder, and people with MDD) have been shown to have higher levels of caffeine consumption after experiencing depressive symptoms (as shown by the Hamilton Rating Scale for depression) ([@B61]; [@B88]). Specially, among youth with depression, there generally is higher caffeine consumption that in the general population ([@B184]). Moreover, the degree of caffeine consumption seems to be a predictor of improvement of somatic symptoms (fatigue among them), and hostility in depressed patients medicated with fluoxetine ([@B189]), suggesting that caffeine could be an effective co-treatment for some of the symptoms of depression. However, it is important to note that, at high doses or in people with susceptibility, caffeine is also known to increase anxiety and insomnia (for a review [@B177]), two side effects that can contribute to worsen MDD. At high doses, however, it has been demonstrated that caffeine may not act as an adenosine receptor antagonist, and other underlying mechanisms seem responsible of its negative effects (for a recent review [@B50]).

Impact of Caffeine on Energy/Fatigability and Behavioral Activation in Humans
=============================================================================

A wide range of studies demonstrate that caffeine can increase alertness and subjective energy, and also reduce fatigue ([@B75], [@B73]; [@B197]; [@B167], [@B164]; [@B90]), thus acting as an ergogenic substance. Caffeine has been demonstrated to increase feelings of efficiency, self-confidence, motivation to work ([@B48]), and to improve psychomotor performance ([@B138]). The behavioral effects of caffeine can be influenced by the baseline arousal levels and also by the nature of the task requirements. It has been argued that the most evident effects of caffeine on fatigue would be expected in situations of low arousal or high fatigue, or in tasks placing high demands on controlled processing ([@B5]; [@B91]). In fact, beneficial effects of caffeine have been observed in people in low states of alertness, such as after benzodiazepines administration ([@B75]), sleep loss ([@B13]; [@B116]), when the person has a cold ([@B164]), or when the experiment is done in the early morning ([@B167]). In addition, a broad range of studies have reported effects of caffeine withdrawal on different markers of motivation using descriptors such as fatigue, decreased energy or vigor, lethargy, amotivation for work, etc. (for a review see [@B76]). For example, in controlled studies, after 10 days of high levels of caffeine consumption (1,250 mg/day), withdrawal results in increased subjective ratings of headache, sleepiness, laziness, and fatigue, as well as decreased alertness, activation and vigor ([@B77]). Abstinence from intermediate doses in daily coffee and cola consumers (579 mg/day), increased ratings of drowsy/sleepy, fatigue/tired, lazy/sluggy/slow-moving, decreased ratings of active/energetic/excited and motivation to work, and impaired performance on psychomotor tasks ([@B92]). Even at low quantities (100 mg/day, in a controlled study), caffeine withdrawal increased ratings of lethargy, fatigue, tiredness, and sluggishness, and decreased ratings of energy, motivation and urge to work ([@B57]).

Effect of Caffeine and Adenosine Antagonists on Classic Animal Models of Depression
===================================================================================

Preclinical studies have been trying to elucidate the effect of caffeine and selective adenosine antagonists on classical animal models of depression ([@B36]). Two of the classic tests for the assessment of antidepressant properties of different substances in rodents are the forced swim test (FST) and the tail suspension test (TST). In the FST animals develop an immobile posture in an inescapable cylinder filled with water ([@B129]; [@B125]). The TST is based on the observation that a mouse suspended by the tail shows alternating periods of agitation and immobility ([@B170]). Classical antidepressants reduce immobility time in these paradigms, which have become the gold standard to evaluate antidepressant effects of multiple drugs or to show depressive symptoms induced by behavioral manipulations ([@B4]). In this regard, learned helplessness has been considered as one of the causes for developing depression in vulnerable individuals that suffer stressful life events. This phenomenon is reproducible in animal models in which the depressive-like state is induced either by chronic uncontrollable and unpredictable stressors (CUS), typically electrical foot-shock ([@B113]), but also by chronic mild stress (CMS) induced by irregular exposure to a combination of different types of stressors over a period of weeks ([@B186]). In addition, animals that develop learned helplessness show a disruption in escape performance as well as decreases in weight gain, increased immobility in the FST or TST, and reduced locomotion, all symptoms associated to some degree with depression ([@B159]). After the administration of substances with antidepressant properties, animals exposed to CUS or CMS display escape-directed behaviors, reducing time of immobility ([@B129]; [@B170]).

All these tests and manipulations have been used to study the therapeutic properties of caffeine and selective adenosine antagonists or genetic deletion of adenosine receptors in rodents. In one of the seminal papers, [@B129] demonstrated that an acute dose of caffeine reduced immobility time in the FST in Sprague-Dawley rats. In later studies, this effect has been confirmed using other strains of rats and mice, after acute or repeated administration of a broad range of doses (3.0--30.0 mg/kg) and using diverse animal tests (FST, TST) ([@B87]; [@B82], [@B81]; [@B141]; [@B78]; [@B105]; [@B173]). In accordance with the effects of caffeine, adenosine A~2A~ receptor antagonists have also been effective in these tests. Thus, SCH58261 and istradefylline (KW6002) reduced total immobility time in both the TST and the FST in mice ([@B36]). SCH58261 also reduced immobility time in a selectively bred 'helpless' mice strain in the TST ([@B36]). Moreover, A~2A~ receptor knockout (A~2A~KO) mice showed reductions in immobility time compared to wild type (WT) animals in both tests ([@B36]).

Using the learned helplessness model for inducing depressive symptoms, it has been demonstrated that acute doses as well as chronic administration of caffeine can reduce the impact of CUS ([@B187]; [@B68]; [@B106]; [@B123]; [@B81]). Thus, pharmacological or genetic blockade of A~2A~ receptors not only prevented but also reversed CUS-induced behavioral and physiological signs of depression such as decreased weight gain, increased corticosterone levels, escape behavior impairments in a shuttle box, increased immobility time in the FST and TST, increased anxiety, and decreased locomotion and spatial reference memory ([@B81]). However, caffeine only reverted the deficits of reference memory but did not reverse mood-related alterations ([@B98]) in mice genetically selected to display 'depressive'-like symptoms ([@B35]). Consistent with these findings, mice that received the selective A~2A~ receptor antagonist istradefylline, as well as the constitutive A~2A~KO mice, were protected from the CUS-induced behavioral impairments in the FST, TST, and memory tests ([@B82]), suggesting a key role for A~2A~ receptors in acute and chronic stress-induced depressive effects.

Based on these results some researchers have focused on adenosine receptor antagonists, including caffeine, as tools to reverse behavioral impairments induced by pharmacological manipulations of the adenosine system ([@B87]; [@B104], [@B106]; [@B187]; [@B68]; [@B123]). Thus, high doses of acutely administered adenosine (50.0--100.0 mg/kg, intraperitoneally IP) ([@B87]), or its analoge 1-chloroadenosine (2.0 mg/kg, IP) induce immobility in the FST in mice, and caffeine as well as theophylline (8.0 mg/kg, IP), reversed this effect ([@B87]). Theophylline, is a psychoactive methylxanthine found in tea and other substances, and is also a metabolite of caffeine that acts as a non-selective adenosine antagonist for A~1~/A~2A~ receptors as well ([@B58]). Increases of adenosine in the central nervous system have been also associated with escape deficits in the inescapable shock paradigm ([@B87]; [@B107]; [@B187]; [@B105]). Thus, it has been demonstrated that intraventricular (ICV) administration of NBTI \[S-(4-nitrobenzyl)-6-theoinosine\], an equilibrative nucleoside transporter (ENT) blocker that increases extracellular adenosine levels blocking its reuptake (see **Figure [2](#F2){ref-type="fig"}**), impaired escape latency in rats ([@B70]; [@B109]) at the same level that rats preexposed to 100 inescapable tail shocks, and potentiates escape impairments produced by 50 inescapable tail shocks ([@B106]). Moreover, ICV administration of erytrho-9(2-hydroxy/3/nonyl adenine (ENHA), a selective adenosine deaminase (ADA) inhibitor which blocks adenosine metabolism, mimicked the effect of inescapable shock ([@B187]). This manipulation increases the concentration of extracellular adenosine by blocking the major degradation pathway. Low doses of caffeine reversed escape deficits induced by EHNA ([@B187]). The reversal effects of caffeine appear to be specific to actions on adenosine receptors, and not as a general stimulant psychomotor effect, since amphetamine exacerbated the behavioral impairments induced by inescapable shocks ([@B104]). In addition, caffeine reversed the escape deficit produced by a bilateral injection of glutamate into the prefrontal cortex of rats ([@B68]). This escape deficit induced by glutamate in the prefrontal cortex has been also associated with enhanced adenosine ([@B127]), since increases in glutamate are counterbalanced by an increase in adenosine production and release ([@B28]; [@B86]).
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Caffeine has also been used to enhance the effect of monoaminergic antidepressants (especially 5-HT/NE uptake inhibitors) that are being used in clinical practice, and have been demonstrated to reduce immobility in classical animal tests of depression. Thus, caffeine at low doses that do not have an effect on their own can potentiate the effects of desipramine, imipramine, duloxetine, fluoxetine and paroxetine, in animals tested on the FST ([@B141]; [@B78]; [@B173]). In addition, a low dose of caffeine can also improve the effect of bupropion (a DA/NE uptake inhibitor), potentiating extracellular levels of DA and NE ([@B78]).

Impact of Adenosine Antagonists on Behavioral Activation: Preclinical Studies
=============================================================================

Tasks measuring behavioral activation and effort-based functions have been suggested as potential animal models for the motivational symptoms of depression ([@B147]; [@B100]; [@B152]). Thus in the animal literature, as in the human data, there are studies showing how caffeine and selective adenosine antagonists affect the willingness to work depending on the demands of the task. In operant tasks with different work demands, caffeine and theophylline produced rate-dependent effects on lever pressing to obtain palatable food in rats ([@B135]). Moderate doses of caffeine and theophylline (5.0--20.0 mg/kg) increased responding on the low task with low response demands; a fixed interval 240 s (FI-240 s) schedule. However, higher doses (10--40 mg/kg) decreased responding on a fixed ratio 20 (FR20), schedule that typically generates high rates of responding ([@B135]). A~2A~ receptor antagonists increased lever pressing in the low effort-demanding task (FI-240 s) but did not suppress the high effort task (FR20) in the dose range tested. In fact, there was a tendency for istradefylline to increase FR20 responding at a moderate dose. A~1~ antagonists failed to increase lever-pressing rate, but decreased FR20 responding at higher doses. These results suggest that the work potentiating effects of methylxanthines are mediated by their actions on adenosine A~2A~ receptors, while their A~1~ receptor antagonistic action could be mediating the suppressant effects.

Progressive ratio (PR) schedules, which require gradually increasing work output, have been also employed to explore the effect of caffeine on motivation to work for sucrose or food in rats and monkeys ([@B11]; [@B9]; [@B139]). Acutely and chronically moderate doses of caffeine (5--25 mg/kg) elevated PR lever pressing for sucrose ([@B9]; [@B139]). Caffeine had no effect on inactive lever presses suggesting that this increase was not due to an increase in general motor activity ([@B139]). Recently, our laboratory has demonstrated that caffeine has differential effects on PR performance depending on baseline individual differences ([@B156]). Caffeine (5.0--10.0 mg/kg) increased responding for a solution containing sucrose in low baseline responders, but decreased lever pressing (10.0--20.0 mg/kg) in high responders ([@B156]). However, in rhesus monkeys intravenous (IV) caffeine (10.0 mg/kg) decreased percent of task completed, and breakpoint in a PR for palatable food ([@B11]), possibly because this dose directly administered in the blood stream resulted in higher levels in the brain.

Thus, from studies in rats and monkeys it seems that high doses of caffeine have an impairing effect on performance in tasks that evaluate willingness to work for a reinforcer if performance is already high. Methylxanthines can help to increase work output when the requirement of the task is low. However, selective A~2A~ receptor antagonists seem to be beneficial independently of the baseline performance, as demonstrated also in goals directed tasks ([@B89]).

Effort Based Decision-Making Deficits Induced by Interference with DA Function: Potential Therapeutic Role of Adenosine Antagonists
===================================================================================================================================

Activational aspects of motivation (i.e., vigor, persistence, work output) are highly adaptative because they enable organisms to overcome obstacles or work-related response costs that separate them from significant stimuli ([@B148], [@B150]; [@B181]). An important feature of adaptive behavior, in the face of work-related challenges, is effort-related decision making. Regularly, organisms must make cost/benefit analyses in which they weigh the value of a stimulus relative to the cost of obtaining it ([@B151], [@B152]). People with MDD show impairments in estimation, anticipation, and recall of reinforcing stimuli ([@B128]), and also show a reduced likelihood of selecting high effort activities in human tasks of effort-related decision making ([@B178]; [@B190]).

Extensive animal data have demonstrated that Acb DA is a key mediator of effort-based decision-making processes (for a review see [@B152]). Interference with DA transmission biases behavior toward less valued rewards that involve less effort and less activity. In these preclinical studies addressing the effort-related decision-making process, animals are given a choice between a more valued reinforcer that can only be obtained by engaging in a more demanding (higher effort) activity vs. a low effort/low value option. One such procedure is a T-maze task that provides an effort-related challenge by having a vertical barrier in the arm with the higher reward density (HD) vs. an arm that contains a lower density of reward (LD) and has no barrier ([@B153]; [@B21]; [@B20]; [@B108]; [@B119]). In this procedure, rodents choose to climb the barrier to get more reward in 90% of the trials, once they have been trained ([@B21]; [@B119]). In operant tasks animals are given a choice between lever pressing for the more preferred reward (in FR5 or PR schedules) vs. approaching and consuming a less preferred reinforcer that is concurrently freely available in the chamber ([@B155]; [@B136]; [@B118]). When tested on the concurrent FR5/free reward choice task, rats typically spend most time pressing the lever for the preferred reward and less consuming freely available food or fluids ([@B155]; [@B118]). In contrast, rats tested on the PR/chow choice task show more individual variability, and tend to disengage more readily from the PR lever pressing component because of the increasing work requirement ([@B136], [@B134]). Research with these concurrent choice tasks has shown that interference with DA transmission via DA depletions or DA receptor antagonism typically biases rodents toward the low effort-low reward option ([@B155]; [@B149]; [@B188]; [@B119]; [@B136], [@B134]; [@B196]).

Using these effort related choice procedures, it has been demonstrated that the catecholamine depleting agent and vesicular transport inhibitor (VMAT-2) tetrabenazine (TBZ), reduces selection of high effort alternatives, but animals compensate by increasing the amount of free less preferred reinforcer consumed ([@B111]; [@B134]; [@B118]; [@B196], [@B195]). TBZ depletes monoamines, with its greatest impact being upon striatal DA ([@B126]; [@B174]; [@B111]). TBZ is used as a therapeutic drug to treat Huntington's disease patients, and it induces symptoms of depression in humans, including fatigue ([@B47]; [@B59]; [@B142]). TBZ has also been used in the FST and TST rodent models of depression ([@B85]; [@B182]). Although the effort-related effects of TBZ are attenuated by the DA uptake blocker bupropion ([@B111]; [@B134]; [@B196]) which is been used as an antidepressant, other classical drugs for the treatment of depression such as the 5-HT uptake inhibitors fluoxetine and citalopram, and the NE uptake inhibitor desipramine, failed to reverse the effects of TBZ, and higher doses even led to further behavioral impairments ([@B196], [@B193],[@B194]).

In addition to DA, adenosine also is involved in these effort related decision-making processes ([@B37], [@B38]; [@B63]; [@B108]; [@B149]). Microinjections of adenosine A~2A~ receptor agonists into the Acb produced effects on instrumental behavior and effort-related choice that resembled those produced by Acb DA receptor antagonism or depletion ([@B45]; [@B103]). In addition, considerable evidence indicates that DA D~2~ and adenosine A~2A~ receptors interact to regulate effort-related functions ([@B149], [@B150]). Thus, adenosine A~2A~ receptor antagonists were able to reverse the shift in choice toward a low effort alternative induced by administration of the D~2~ antagonists haloperidol and eticlopride ([@B37], [@B38]; [@B108]; [@B154]; [@B188]; [@B119], [@B120]). Moreover, A~2A~ KO mice were resistant to the effects of haloperidol on performance of the T-maze barrier task ([@B119]). Recently, it has been demonstrated that A~2A~ KO mice are also resistant to the anergia inducing effects of D~2~ antagonism in a paradigm in which animals can choose between exercising on a much preferred running wheel or sedentary consuming sweet food ([@B18]). In contrast, adenosine A~1~ antagonists were ineffective at reversing the effort-related effects of either the D~1~ receptor antagonist ecopipam or the D~2~ receptor antagonist eticlopride ([@B149]; [@B112]; [@B119]).

The therapeutic effect of caffeine and theophylline on effort-related choice behavior after the administration of D~2~ antagonists has also been reported in rats tested on the concurrent FR5/chow feeding choice task. Caffeine partially attenuated the effects of haloperidol, increasing the lever pressing and decreasing the free chow intake in haloperidol-treated rats ([@B154]) and the same pattern of results were observed in a more recent study in which caffeine reversed the anergia-like effect induced by TBZ in an adapted version of the T-maze task with RW ([@B18]) increasing the time running (effortful option) and decreasing the time spent eating free available sweet pellets (sedentary option) ([@B94]). This behavioral effect was supported by changes in an intracellular marker of DA neurotransmission \[phosphorylated form of DARPP-32; pDARPP-32(Thr34)\] in the striatum ([@B94]). Similarly, theophylline reversed the effects induced by this D~2~ antagonist in mice tested in the T-maze barrier task ([@B119]). Furthermore, several papers have reported that the adenosine A~2A~ receptor antagonist MSX-3 can reverse the effort-related effects of TBZ across multiple tasks ([@B111]; [@B134]; [@B196]). All these findings suggest that the reversal effects induced by methylxanthines on anergia induced by DA D~1~ and D~2~ receptor antagonism could be mediated mainly by A~2A~ receptors.

Mental fatigue associated with high attentional demands can also be overcome by the use of psychostimulants such as amphetamine or caffeine ([@B160]; [@B124]). For instance, caffeine restores memory performance in sleep-deprived or aged humans, a finding replicated in rodent animal models ([@B25]). In cost/benefit decision-making tasks involving the evaluation of the costs related to high attention-demands, rats can choose between engaging in hard trials (difficult visuospatial discrimination) leading to more reward versus easy trials leading to less reward ([@B15]). Under basal conditions, animals chose high effort/high reward trials more than low-effort/low reward trials. However, there are substantial baseline differences. Amphetamine increases the selection of high effort/high reward trials in animals that usually do not choose this option, but it decreases the selection of the high cognitive demand trials in animals that usually choose them. A high dose of caffeine decreased choice of high effort/high reward trials in animals that usually choose them as did amphetamine, but it did not increase the selection in the ones that usually did not choose them ([@B15]).

A~2A~ Receptor Antagonists have Therapeutic Actions on Cytokine-Induced Fatigue
===============================================================================

Cytokines are signaling molecules for the immune system mediating physiological responses to infection ([@B27]). These molecules also mediate a set of behavioral signs that include depressed activity and loss of interest or motivation ([@B84]). Compared to the general population, depressed patients have elevated levels of proinflammatory cytokines such as tumor necrosis factor alpha (TN-alpha) interleukin-1β (IL-1β), and IL-6 ([@B33]; [@B66]). Fatigue, loss of energy and psychomotor slowing are reported to occurred in patients receiving treatment with IFN-α or with high levels of IL-6 ([@B102]; [@B54]). Moreover, many inflammatory stimuli have been found to target reductions in ventral striatal neural function, and decreased synthesis of striatal DA, which is possibly related to symptoms of reduced motivation and motor retardation ([@B41]). Studies with IL-6 indicate that this cytokine is responsive to stress, and is implicated in the production of depression-like effects in mice, including actions on traditional tests such as the FST, TST, and social interaction tests ([@B171]). In anergia related studies, IL-6 and IL-1β reduced the tendency to work for food when an alternative food source (concurrently available chow) could be obtained through minimal effort ([@B110]; [@B192]).

Brain cytokine signaling involves adenosine signaling at adenosine A~2A~ receptors ([@B62]). These receptors regulate IL-1β and LPS linked to pathological behavioral and physiological responses such as anxiety ([@B14]) or neuroinflammation ([@B10]; [@B161]). Adenosine A~2A~ receptor signaling provides inhibitory feedback on proinflammatory cytokine signaling in peripheral immune cells ([@B163]). Thus, the effects of IL-6 and IL-1β were attenuated through co-administration of the adenosine A~2A~ receptor antagonist MSX-3, as well as the major stimulant methylphenidate, which blocks catecholamine uptake ([@B110]; [@B194]). Though previous work has shown that MSX-3 had no effect of FR5/chow-feeding choice performance when administered on its own ([@B37]), MSX-3 produced a very robust reversal of the behavioral effects of IL-6 and IL-1β, restoring the baseline behavioral pattern of responding (i.e., increasing lever pressing and decreasing chow consumption) to a normal level ([@B110]; [@B194]). These results highlight the therapeutic potential of adenosine A~2A~ receptor antagonism for pathologies related to neuroinflammation ([@B161]; [@B24]).

Anergia and Fatigue Influence Decision-Making in Humans with Depression
=======================================================================

Translational studies in humans have implemented tasks that evaluate the decision-making process in normal as well as psychiatric patients. The effort expenditure for rewards task (EEfRT; [@B179]), is based on the operant lever pressing choice tasks described above ([@B155]). In the human version of this task, subjects choose on each trial between a high cost/high reward option (HC/HR) and low cost/low reward option (LC/LR) to obtain different monetary rewards. The HC/HR trials required 100 button presses with the non-dominant pinky finger within 21 s, and subjects were eligible to win higher amounts that varied per trial between \$1.24--4.30. In contrast, the LC/LR option only required 30 button presses with the dominant index finger during 7 s, and subjects could win \$1.00 for each successfully completed trial.

Patients with MDD were significantly less likely to make HC/HR choices relative to controls, and this result was not related with depression-related differences in psychomotor speed ([@B178]). The effect of caffeine on this task in depressed patients has not been explored, but it was assessed in normal subjects. Thus, in the normal population, caffeine (200 mg), significantly increased the speed of responses compared to placebo ([@B183]). However, caffeine did not have an effect on percentage of HC/HR choices ([@B183]). In fact, it decreased effortful choices in high cardiovascular responders (subjects with high arterial pressure in response to caffeine) ([@B183]). These results contrast with studies showing that, during exercise, caffeine decreases the perception of effort in humans ([@B32]), improving performance particularly for endurance testing ([@B31]). Thus, caffeine may only improve performance in highly demanding situations.

Conclusion and Further Directions
=================================

Although many available treatments for MDD provide relief for individuals with depressed mood, no single therapeutic modality provides a full and permanent recovery across all the symptoms of MDD in the majority of patients ([@B101]). Clinicians have come to emphasize the importance of taking into account effort-related motivational symptoms in depression ([@B180]; [@B168]; [@B30]; [@B152]). Decreased psychomotor speed, referred to clinically as psychomotor retardation, fatigue and anergia are cardinal symptoms of MDD that have been associated with poor antidepressant treatment response ([@B53]). Even among patients in remission, anergia and psychomotor retardation are pervasive symptoms ([@B55]). Thus, novel pharmacological targets are being investigated in clinical and preclinical studies.

There are promising results shown in epidemiological studies as well as in animal models, about the impact of caffeine and selective adenosine receptor antagonists on these symptoms. Is worth noting that the epidemiological studies have revealed a relation between caffeine consumption and decreased risk for developing depression ([@B96]), and some reports demonstrate the use of caffeine as a self-medication among depressed patients ([@B88]). However, it seems clear that more controlled studies are needed to explore the effect of caffeine across a wide variety of depressive symptoms, and it seems necessary to test more selective drugs for A~2A~ receptors.

Systematic studies of the effects of methylxanthines on animal models of depression and anergia have shown efficacy at improving parameters related with initiation and maintenance of behavior in order to escape an aversive situation, but also in order to pursue valued reinforcers and achieve goals ([@B87]; [@B187]; [@B68]; [@B106]; [@B135]; [@B123]). As with the human data, these therapeutic actions depend upon the dose administered, since high doses of caffeine and theophylline not only do not improve depressive symptoms, but can in fact promote anxiety ([@B17]; [@B93]). Moreover, it is important to take into consideration that the use of high doses of caffeine and other methylxanthiness, specially, among the elder, could also have severe side effects such as tachycardia, gastric discomfort, or insomnia ([@B51]). All these side effects could in fact worse the symptoms of MDD. Both in humans and in animal studies, the therapeutic actions of methylxanthines also seem to be dependent on the basal estate; for instance they seem to be effective when subjects are in a state or fatigue, tiredness or sleepiness ([@B74]; [@B167]; [@B13]), or when the DArgic system is compromised. Such effects are less evident when humans and rodents are under "normal" conditions.

Several A~2A~ selective receptor antagonists have also shown to reverse motivational impairments induced by DA antagonism or depletion in animal models of anergia ([@B37]; [@B108]; [@B154]; [@B119]; [@B18]). Furthermore, a recent report indicates that istradefylline can improve fatigue-related symptoms in Parkinson's disease patients ([@B1]; [@B145]). Adenosine A~2A~ receptors might be involved in these processes through their interaction with DA D~2~ receptors in the Acb, region highly involved in the activational component of motivation (for a review see [@B150]).

Consistent with these findings, it has been demonstrated that the rank order of clinical effectiveness in depressed patients with psychomotor retardation, paralleled the specificity of antidepressants as DA-mimetic agents ([@B132]). Antidepressants such as bupropion have demonstrated to have therapeutical effects on motivational symptoms in humans ([@B115]) and in animal models or anergia ([@B111]; [@B134]; [@B196]). In animal studies, caffeine was shown to improve the effects of antidepressants such as bupropion, duloxetine, and desipramine ([@B141]; [@B78]; [@B79]; [@B173]). These studies have led to the suggestion that caffeine could be used as an enhancer of antidepressant pharmacotherapy (for a review see [@B80]), a suggestion that is consistent with the clinical trials for antiparkinsonian effects showing that A~2A~ receptor antagonists can be a good adjuvant in the treatment of motor symptoms ([@B67]).

However, determination of the predominant symptomatology is key to therapeutic success. Recent neuroimage data from patients with depression indicate that they can be clustered based on four different connectivity profiles ('biotypes') that are associated with differences in clinical symptoms ([@B34]). Thus, reduced connectivity in anterior cingulate and orbitofrontal areas supporting motivation was most severe in biotypes 1 and 2, which were characterized partly by increased anergia and fatigue ([@B34]). This type of objective diagnostic can help to identify different type of patients that could benefit from different type of antidepressant therapies. For instance, in patients affected by anxious depression a selective inhibitor of 5-HT reuptake appears to be more effective than a selective inhibitor of DA reuptake ([@B133]), and caffeine in those type of depressed patients may worsen the anxiety symptomatology. However, adenosine A~2A~ receptor antagonism may offer an alternative therapeutic strategy for treating effort-related motivational dysfunctions in humans, probably with lower abuse liability and fewer major stimulant motor effects compared to DA uptake inhibitors.
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